Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity

Pharmacotherapy. 1994 Mar-Apr;14(2):147-52.

Abstract

Study objectives: To evaluate the pharmacodynamic antibacterial activity of ticarcillin-clavulanic acid (T-C) and ampicillin-sulbactam (A-S) combinations against reference bacterial strains in patients with end-stage renal disease maintained on long-term hemodialysis.

Design: Randomized, crossover, controlled study.

Setting: National Institutes of Health-funded general clinical research unit in a Veterans Administration Medical Center.

Patients: Nine adult men with end-stage renal disease maintained on long-term hemodialysis. Two subjects did not complete the study due to problems of vascular access, and another withdrew for personal reasons.

Interventions: On a nondialysis day, each subject was randomly administered either T-C 3.1 g or A-S 3 g as a slow intravenous infusion over 30 minutes. Serial blood samples were collected for measurement of antibiotic serum concentrations and determination of serum bactericidal titers. Following a washout period, the study was repeated with the alternative antibiotic combination.

Measurements and main results: The mean observed apparent beta-half-life of clavulanic acid was substantially shorter than that for the other three drugs. The bactericidal activity of both A-S and T-C against non-beta-lactamase-producing (N beta-LP) strains of S. aureus and E. coli was consistently high, as indicated by geometric mean SBTs of at least 1:5 at 24 hours. Against beta-lactamase-producing (beta-LP) S. aureus, the geometric mean SBTs for A-S were at least 1:25 throughout the study period, while the geometric mean SBTs for T-C decreased over 24 hours from 1:29 to 1:6. Against beta-LP E. coli, the bactericidal activities for both A-S and T-C were poor, with geometric mean peak SBTs of only 1:6 and 1:3, respectively. The geometric mean SBT for T-C against this E. coli strain had declined to 1:1 at 6 hrs.

Conclusion: Increasing the dosing interval for T-C in patients with end-stage renal disease may lead to periods of insufficient clavulanic acid to protect ticarcillin from beta-lactamase degradation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Ampicillin / blood
  • Ampicillin / pharmacokinetics
  • Ampicillin / pharmacology
  • Clavulanic Acids / blood
  • Clavulanic Acids / pharmacokinetics
  • Clavulanic Acids / pharmacology
  • Drug Therapy, Combination / blood*
  • Drug Therapy, Combination / pharmacokinetics
  • Drug Therapy, Combination / pharmacology
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology
  • Humans
  • Kidney Failure, Chronic / metabolism*
  • Kidney Failure, Chronic / microbiology
  • Male
  • Middle Aged
  • Serum Bactericidal Test*
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / enzymology
  • Sulbactam / blood
  • Sulbactam / pharmacokinetics
  • Sulbactam / pharmacology
  • Ticarcillin / blood
  • Ticarcillin / pharmacokinetics
  • Ticarcillin / pharmacology
  • beta-Lactamase Inhibitors

Substances

  • Clavulanic Acids
  • beta-Lactamase Inhibitors
  • sultamicillin
  • Ampicillin
  • ticarcillin-clavulanic acid
  • Ticarcillin
  • Sulbactam